Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Video

Why Do We Need Dedicated DES Diabetic Patients

November 19, 2019

Video

Why Do We Need Dedicated DES Diabetic Patients

November 19, 2019

Video

Step-by-step treatment strategy complex diabetic patient Albuminus DES

November 5, 2019

Video

Albuminus DES in CHIP cases outcomes

November 5, 2019

Video

Sirolimus Coated Balloon for salvage thrombus arteriovenous graft - Interim results and future RCT design

November 5, 2019

Video

FDA Pivotal Clinical Trial Design and Beyond

November 4, 2019

Video

» Topical Discussion

Impact of Ultrathin Strut Stents and the Clinical Outcomes: An International Panel Discussion

October 10, 2019

Video

» Topical Discussion

SYNERGY BP-DES & Optimizing Antiplatelet Therapy after PCI in High-Bleeding Risk Patients

October 8, 2019

Video

BIODEGRADE: A Large-Scale Randomized Trial of a Thin-Strut Bioabsorbable Polymer-Based DES vs. a Thick-Strut Bioabsorbable Polymer-Based DES in an All-Comers Population With Coronary Artery Disease

September 29, 2019

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Dean Kereiakis About the First Human Use of a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor (RUC-4) Designed for STEMI Point of Care Treatment

September 26, 2019

Advertisement

Why Do We Need Dedicated DES Diabetic Patients

Why Do We Need Dedicated DES Diabetic Patients

Step-by-step treatment strategy complex diabetic patient Albuminus DES

Albuminus DES in CHIP cases outcomes

Sirolimus Coated Balloon for salvage thrombus arteriovenous graft - Interim results and future RCT design

FDA Pivotal Clinical Trial Design and Beyond

Impact of Ultrathin Strut Stents and the Clinical Outcomes: An International Panel Discussion

SYNERGY BP-DES & Optimizing Antiplatelet Therapy after PCI in High-Bleeding Risk Patients

BIODEGRADE: A Large-Scale Randomized Trial of a Thin-Strut Bioabsorbable Polymer-Based DES vs. a Thick-Strut Bioabsorbable Polymer-Based DES in an All-Comers Population With Coronary Artery Disease

Dr. C. Michael Gibson Talks With Dr. Dean Kereiakis About the First Human Use of a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor (RUC-4) Designed for STEMI Point of Care Treatment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content